Insulet Corporation

NASDAQ:PODD

Medical - Devices

Healthcare
$139.98 -2.82%

-$4.17 today

Market cap
$9.71B
Beta
1.13
P/E (TTM)
33.2
EPS (TTM)
$4.33
52W Low $140.63High $354.88

Volume 2.09M

Average 1.32M

PODD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Insulet CorporationNASDAQ: PODD

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $19.6M rose 161.3% year over year, ahead of the +22.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 8.0% from the prior quarter. Over 3 fiscal years it compounded at +15.3% a year.

Context

  • Stock-based compensation amounted to 2.3% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +161.3% holds above the trailing-twelve-month pace of +22.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.6M-8.0% QoQ
Last fiscal yearDec 2025
$62.7M-9.5% YoY
LTMJun 2026
$77.9M+22.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+161.3%——
1 year-9.5%——
3-year CAGR+15.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
62.7M USD
Year-over-year change
-9.5%
4-year CAGR
+16.2%

Stock-Based Compensation vs competitors

How PODD compares with its peers on the latest reported figures

  • PODD's LTM Jun 2026 stock-based compensation of $77.9M is the 3rd largest of the 5 companies compared; the peer median is $50.77M.
  • Its year-over-year change of +22.1% is the 2nd highest of 5, against a peer median of +6.0%.
  • Stock-based compensation amounts to 2.6% of revenue for PODD, versus a peer median of 12.6%.
PODD Competitors Peer median
Stock-Based Compensation for PODD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DXCMDexCom, Inc.LTM Jun 2026$162.4M -2.3%+8.1%3.3%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$82.55M -21.3%+2.8%8.0%
PODDInsulet CorporationLTM Jun 2026$77.9M +22.1%+15.3%2.6%
BBNXBeta Bionics, Inc.LTM Mar 2026$18.99M +142.5%+39.0%17.2%
SENSSenseonics Holdings, Inc.LTM Mar 2026$10.59M +14.3%+5.6%26.0%
Peer median (excluding PODD) $50.77M+6.0%+6.8%12.6%

Competitors are the stored peer set for PODD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income16.8M4.6M206.3M418.3M247.1M
Depreciation & Amortization57.4M63.2M72.8M80.8M90.4M
Deferred Income Tax0(1M)500K(136.9M)62.2M
Stock-Based Compensation34.4M40.9M48.3M69.3M62.7M
Change in Working Capital(263.6M)(2.5M)(190.6M)(17M)(23.1M)
Accounts Receivables(71.3M)(51.8M)(154.2M)(10.4M)(140.2M)
Inventory(154.4M)(49.1M)(53.6M)(32.4M)(10.6M)
Accounts Payables(15.6M)(2.4M)(11M)2.2M49.2M
Other Working Capital(22.3M)100.8M28.2M23.6M78.5M
Other Non-Cash Items86.9M13.8M8.4M15.8M130M
Operating Cash Flow(68.1M)119M145.7M430.3M569.3M
Capital Expenditures(122.7M)(157.3M)(75.6M)(124.9M)(191.6M)
Acquisitions (Net)0(26M)(3M)00
Purchases of Investments0(7.8M)(7.2M)(12.2M)0
Sales of Investments40M0000
Other Investing Activities0000(31.1M)
Investing Cash Flow(82.7M)(191.1M)(119.4M)(146.2M)(222.7M)
Debt Repayment49.4M(39.8M)(27M)(40.6M)(708.1M)
Common Stock Issued23.5M16.3M26.9M20.1M33.9M
Common Stock Repurchased0000(59.6M)
Dividends Paid00000
Other Financing Activities(32.2M)(16.8M)(13.5M)(7.6M)138.5M
Financing Cash Flow40.7M(40.3M)(13.6M)(28.1M)(595.3M)
Effect of Forex Changes(5.5M)(4.3M)1.8M(6.8M)11.5M
Net Change in Cash(115.6M)(116.7M)14.5M249.2M(237.3M)
Free Cash Flow(190.8M)(38.3M)70.1M305.4M377.7M

Insulet Corporation

NASDAQ:PODD

Intrinsic Alpha fair value

Locked

Current Price

$139.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.